Merck & Co. announced that the U.S. Food and Drug Administration approved an expanded label for its once‑yearly injectable parasite‑control product, BRAVECTO QUANTUM, on March 18 2026. The new indication adds protection against the Asian longhorned tick (Haemaphysalis longicornis) and the Gulf Coast tick (Amblyomma maculatum) for dogs, extending the drug’s 12‑month coverage for these species.
The approval builds on the product’s original FDA approval on July 10 2025 and targets two tick species that are expanding geographically and pose veterinary health risks. The Asian longhorned tick, first detected in the United States in 2017, can infest livestock and potentially transmit diseases, while the Gulf Coast tick can transmit American canine hepatozoonosis. By covering these ticks, Merck offers a single‑dose solution that protects against a broader range of clinically important tick species.
The expanded label strengthens Merck’s Animal Health segment, which generated $6.35 billion in revenue in fiscal 2025, up 8.12% from $5.9 billion in 2024. BRAVECTO sales reached $209 million in Q4 2025, a 6% increase from the prior quarter. The expanded label is expected to broaden the addressable market for the product and reinforce Merck’s leadership in parasiticide solutions.
"For more than a decade, BRAVECTO has set the benchmark for extended‑duration flea and tick protection, and today's label expansion reinforces our leadership in parasiticide innovation," said Meg Conlon, DVM, executive director of U.S. Companion Animal Veterinary Services. "With BRAVECTO QUANTUM, Merck Animal Health continues to deliver the longest‑lasting protection available in a single dose – now covering an even broader range of clinically important tick species."
The expanded label positions BRAVECTO QUANTUM as the longest‑lasting flea and tick protection available for dogs in the United States, giving veterinarians a comprehensive, single‑dose option that can improve compliance and reduce the need for multiple treatments. The move is expected to drive additional sales volume and support Merck’s strategy of expanding its animal‑health portfolio through innovative, high‑value products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.